To sum up, Oroxylin A could increase the sensitivity of CML cells to IM in human BM microenvironment by inhibiting CXCR4/β-catenin/P-gp pathway. This evidence concerns the gene CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive.